Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00358917
First received: July 28, 2006
Last updated: April 7, 2011
Last verified: April 2011
Results First Received: November 12, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Human Immunodeficiency Virus Infections
Intervention: Drug: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
LPV/r 800/200 mg QD Tablet lopinavir/ritonavir 800/200 milligram (mg) once daily (QD) tablet
LPV/r 400/100 mg BID Tablet lopinavir/ritonavir 400/100 milligram (mg) twice daily (BID) tablet

Participant Flow:   Overall Study
    LPV/r 800/200 mg QD Tablet     LPV/r 400/100 mg BID Tablet  
STARTED     300     299  
COMPLETED     234     230  
NOT COMPLETED     66     69  
Adverse Event                 14                 21  
Withdrawal by Subject                 5                 7  
Lost to Follow-up                 20                 17  
Noncompliance                 12                 11  
Death                 2                 3  
Virologic failure                 11                 8  
Unable to Continue Participation                 2                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
LPV/r 800/200 mg QD Tablet lopinavir/ritonavir 800/200 mg once daily (QD) tablet
LPV/r 400/100 mg BID Tablet lopinavir/ritonavir 400/100 mg twice daily (BID) tablet
Total Total of all reporting groups

Baseline Measures
    LPV/r 800/200 mg QD Tablet     LPV/r 400/100 mg BID Tablet     Total  
Number of Participants  
[units: participants]
  300     299     599  
Age  
[units: years]
Mean ± Standard Deviation
  40.4  ± 9.22     40.8  ± 8.63     40.6  ± 8.92  
Gender  
[units: participants]
     
Female     103     103     206  
Male     197     196     393  
Received Prior Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)  
[units: participants]
     
Received Prior NNRTI     264     241     505  
Did Not Receive Prior NNRTI     36     58     94  
Received Prior Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTI)  
[units: participants]
     
Received Prior NRTI     299     297     596  
Did Not Receive Prior NRTI     1     2     3  
Received Prior Protease Inhibitor (PI)  
[units: participants]
     
Received Prior PI     140     136     276  
Did Not Receive Prior PI     160     163     323  
Cluster of Differentiation 4 Single-Positive Thymocyte (CD4+ T) Cell Count  
[units: cells/microliter]
Mean ± Standard Deviation
  239.3  ± 158.39     268.3  ± 183.55     253.9  ± 171.98  
Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Level  
[units: log10¬†copies/milliliter¬†(mL)]
Mean ± Standard Deviation
  4.26  ± 0.826     4.26  ± 0.809     4.26  ± 0.817  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants Responding at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm   [ Time Frame: Week 48 (End of Study) ]

2.  Secondary:   Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Levels < 50 Copies/Milliliter (mL) at Week 48   [ Time Frame: Week 48 (End of Study) ]

3.  Secondary:   Mean Change From Baseline to Week 48 in Cluster of Differentiation 4 Single-Positive Thymocyte (CD4+ T) Cell Counts   [ Time Frame: Week 48 (End of Study) ]

4.  Secondary:   Virologic Response (HIV-1 RNA <50 Copies/mL) at Week 48 for Participants With 0-2 Protease Inhibitor Substitutions at Baseline Associated With Reduced Response to Lopinavir/Ritonavir   [ Time Frame: Week 48 (End of Study) ]

5.  Secondary:   Percentage of Participants With New Primary Protease Mutations at Week 48   [ Time Frame: Week 48 (End of Study) ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Medical Information Specialist
Organization: Abbott
phone: 800-633-9110


No publications provided


Responsible Party: Barry Bernstein, MD, Project Director, Abbott
ClinicalTrials.gov Identifier: NCT00358917     History of Changes
Other Study ID Numbers: M06-802
Study First Received: July 28, 2006
Results First Received: November 12, 2009
Last Updated: April 7, 2011
Health Authority: United States: Food and Drug Administration